Cowppli-Bony Anne, Uhry Zoé, Remontet Laurent, Voirin Nicolas, Guizard Anne-Valérie, Trétarre Brigitte, Bouvier Anne-Marie, Colonna Marc, Bossard Nadine, Woronoff Anne-Sophie, Grosclaude Pascale
aFrench Network of Cancer Registries (FRANCIM), Toulouse bTarn Cancer Registry, Claudius Regaud Institute, IUCT-O, Toulouse cLEASP - UMR 1027 INSERM Toulouse III University, Toulouse dLoire-Atlantique Vendée Cancer Registry, Nantes eSanté Publique France, Saint Maurice fDepartment of Biostatistics, University Hospital of Lyon gUniversity of Lyon, Lyon hUniversity of Lyon 1, Villeurbanne iUMR5558, Biometry and Evolutionary Biology Laboratory (LBBE), BioMaths-Health Department, CNRS, Villeurbanne jCalvados General Tumor Registry, Caen kHérault Cancer Registry, Montpellier lDigestive Cancer Registry of Burgundy, INSERM U866, University Hospital of Dijon, University of Burgundy, Dijon mIsère Cancer Registry, Grenoble nDoubs and Belfort Territory Cancer Registry, University Hospital of Besançon, Besançon, France.
Eur J Cancer Prev. 2017 Nov;26(6):461-468. doi: 10.1097/CEJ.0000000000000372.
This study provides updates of net survival (NS) estimates at 5, 10, and 15 years as well as survival trends for 35 solid cancers in France using data from 19 population-based cancer registries. The study considered all cases of solid cancer diagnosed between 1989 and 2010 in patients older than 15 years of age who were actively followed up until 30 June 2013. NS was estimated using the Pohar-Perme method. The age-standardized NS used the international cancer survival standard weights. The 5-year age-standardized NSs ranged from 4% (pleural mesothelioma) to 93% (prostate) in men and from 10% (pancreas) to 97% (thyroid) in women. The 10-year age-standardized NSs ranged from 2% (pleural mesothelioma) in both sexes to 95% (testis) in men and 91% (thyroid) in women. The most frequent cancers (namely, breast and prostate cancers) had the highest NSs: 87 and 93% at 5 years and 78 and 84% at 10 years, respectively. Several cancers (especially lung, pancreas, and liver cancer) had very poor prognoses (5-year NSs under 20%). Fifteen-year NSs remained high for testis cancer. In most cancers, 5- and 10-year age-standardized NSs increased between 1989 and 2010. Advanced age was associated with a poor prognosis and little improvement in survival. The increases in cancer survival are probably related to earlier diagnosis and therapeutic advances over the last decade. However, poor prognoses are still found in some alcohol-related and tobacco-related cancers and in elderly patients, highlighting the need for more prevention, diagnosis, and treatment efforts.
本研究利用来自19个基于人群的癌症登记处的数据，提供了法国35种实体癌在5年、10年和15年时的净生存率（NS）估计值更新情况以及生存趋势。该研究纳入了1989年至2010年间确诊的所有15岁以上实体癌病例，这些患者接受了积极随访直至2013年6月30日。NS采用Pohar-Perme方法进行估计。年龄标准化的NS使用国际癌症生存标准权重。男性5年年龄标准化NS范围为4%（胸膜间皮瘤）至93%（前列腺癌），女性为10%（胰腺癌）至97%（甲状腺癌）。两性10年年龄标准化NS范围均为2%（胸膜间皮瘤），男性为95%（睾丸癌），女性为91%（甲状腺癌）。最常见的癌症（即乳腺癌和前列腺癌）NS最高：5年时分别为87%和93%，10年时分别为78%和84%。几种癌症（尤其是肺癌、胰腺癌和肝癌）预后很差（5年NS低于20%）。睾丸癌15年NS仍然很高。在大多数癌症中，1989年至2010年间5年和10年年龄标准化NS有所增加。高龄与预后不良及生存改善不大相关。癌症生存率的提高可能与过去十年中更早的诊断和治疗进展有关。然而，在一些与酒精和烟草相关的癌症以及老年患者中仍发现预后不良，这凸显了加强预防、诊断和治疗工作的必要性。
Eur J Cancer Prev. 2017-11
Int J Cancer. 2013-1-18
Epidemiol Prev. 2016
Epidemiol Prev. 2013
Clin Transl Oncol. 2017-7-17
Curr Cardiol Rep. 2025-6-25
J Natl Cancer Cent. 2023-12-28
Sultan Qaboos Univ Med J. 2023-8
Therap Adv Gastroenterol. 2020-9-20
Zotero 插件